{"contacts": [{"terms": [{"accession": "MS:1000586", "name": "contact name", "value": "John Koomen"}, {"accession": "MS:1000589", "name": "contact email", "value": "john.koomen@moffitt.org"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Moffitt Cancer Center"}, {"accession": "MS:1002037", "name": "dataset submitter"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Uwe Rix, PhD"}, {"accession": "MS:1000589", "name": "contact email", "value": "uwe.rix@moffitt.org"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Moffitt Cancer Center Tampa, FL, USA"}]}], "datasetFiles": [{"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD020520/20141205_CKRix_PD389.RAW"}, {"accession": "MS:1002848", "name": "Result file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD020520/20141205_CKRix_PD389.RAW (F008716).mzid.gz"}, {"accession": "MS:1002850", "name": "Peak list file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD020520/20141205_CKRix_PD389.RAW (F008716).mzid_20141205_CKRix_PD389.RAW_(F008716).MGF"}, {"accession": "MS:1002850", "name": "Peak list file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD020520/20141205_CKRix_PD389.RAW_(F008716).dta"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD020520/20141205_CKRix_PD390.RAW"}, {"accession": "MS:1002848", "name": "Result file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD020520/20141205_CKRix_PD390.RAW (F008717).mzid.gz"}, {"accession": "MS:1002850", "name": "Peak list file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD020520/20141205_CKRix_PD390.RAW (F008717).mzid_20141205_CKRix_PD390.RAW_(F008717).MGF"}, {"accession": "MS:1002850", "name": "Peak list file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD020520/20141205_CKRix_PD390.RAW_(F008717).dta"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD020520/20141205_CKRix_PD391.RAW"}, {"accession": "MS:1002848", "name": "Result file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD020520/20141205_CKRix_PD391.RAW (F008718).mzid.gz"}, {"accession": "MS:1002850", "name": "Peak list file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD020520/20141205_CKRix_PD391.RAW (F008718).mzid_20141205_CKRix_PD391.RAW_(F008718).MGF"}, {"accession": "MS:1002850", "name": "Peak list file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD020520/20141205_CKRix_PD391.RAW_(F008718).dta"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD020520/20141205_CKRix_PD392.RAW"}, {"accession": "MS:1002848", "name": "Result file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD020520/20141205_CKRix_PD392.RAW (F008719).mzid.gz"}, {"accession": "MS:1002850", "name": "Peak list file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD020520/20141205_CKRix_PD392.RAW (F008719).mzid_20141205_CKRix_PD392.RAW_(F008719).MGF"}, {"accession": "MS:1002850", "name": "Peak list file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD020520/20141205_CKRix_PD392.RAW_(F008719).dta"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD020520/F008716.dat"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD020520/F008717.dat"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD020520/F008718.dat"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD020520/F008719.dat"}], "description": "PARP1 inhibitors (PARP1is) display single-agent anticancer activity in small cell lung cancer (SCLC) and other neuroendocrine tumors independent of BRCA1/2 mutations. Here, we determined the differential efficacy of multiple clinical PARP1is in SCLC cells. Compared to the other PARP1is (rucaparib, olaparib and niraparib), talazoparib displayed the highest potency across SCLC, also  in SLFN11-negative cells. Chemical proteomics identified PARP16 as a unique talazoparib target in addition to PARP1. Silencing PARP16 significantly reduced cell survival, particularly in combination with PARP1 inhibition. Drug combination screening revealed talazoparib synergy with the WEE1/PLK1 inhibitor, adavosertib. Global phosphoproteomics identified disparate effects on cell cycle and DNA damage response signaling, illustrating underlying mechanisms. Synergy with adavosertib was more pronounced for talazoparib than olaparib and silencing PARP16 further reduced cell survival in combination with olaparib and adavosertib. Together, these data suggest that PARP16 contributes to talazoparib\u2019s overall mechanism of action and constitutes a new actionable target in SCLC.", "fullDatasetLinks": [{"accession": "MS:1002852", "name": "Dataset FTP location", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD020520"}, {"accession": "MS:1001930", "name": "PRIDE project URI", "value": "http://www.ebi.ac.uk/pride/archive/projects/PXD020520"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD020520"}, {"accession": "MS:1001922", "name": "Digital Object Identifier (DOI)", "value": "10.6019/PXD020520"}], "instruments": [{"accession": "MS:1000449", "name": "LTQ Orbitrap"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "PARP inhibitor, PARP16, Talazoparib, Adavosertib, PARP1, Proteomics, Polypharmacology, Off-target, Breast cancer"}], "modifications": [{"accession": "MOD:00425", "name": "monohydroxylated residue"}, {"accession": "MOD:00397", "name": "iodoacetamide derivatized residue"}], "publications": [{"terms": [{"accession": "MS:1002858", "name": "Dataset with its publication pending"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Homo sapiens (Human)"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "9606"}]}], "title": "The non-canonical PARP1 inhibitor target, PARP16, contributes to talazoparib polypharmacology and synergy with WEE1 inhibitors: Chemical Proteomics Cal51"}